COMBINATION OF CNDAC WITH A 2-SUBSTITUTED-4-HETER0ARYL-PYRIMIDINE AMINE AND USE THEREOF IN THE TREATMENT OF A PROLIFERATIVE DISORDER

摘要

A first aspect of the invention relates to a combination comprising CNDAC, or a prodrug thereof, and a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein: R<SUP>1</SUP> is alkyl; R<SUP>2</SUP> and R<SUP>3</SUP> are each independently selected from H and alkyl; and R<SUP>4</SUP> is a heteroalicyclic group optionally substituted by one or more substituents selected from alkyl, CO-alkyl and aralkyl. A second aspect of the invention relates to a pharmaceutical product comprising a compound of formula (I),, or a pharmaceutically acceptable salt thereof, and CNDAC, or a prodrug thereof, as a combined preparation for simultaneous, sequential or separate use in therapy. A third aspect of the invention relates to a method of treating a proliferative disorder, said method comprising simultaneously, sequentially or separately administering a compound of formula I, or a pharmaceutically acceptable salt thereof, and CNDAC, or a prodrug thereof, to a subject.